Cancer Cachexia - Pipeline Review, H2 2016

  • ID: 3832309
  • Drug Pipelines
  • 108 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Eli Lilly and Company
  • Helsinn Healthcare S.A.
  • Incyte Corporation
  • MORE
Cancer Cachexia - Pipeline Review, H2 2016

Summary

‘Cancer Cachexia - Pipeline Review, H2 2016’, provides an overview of the Cancer Cachexia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
- The report reviews pipeline therapeutics for Cancer Cachexia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cancer Cachexia therapeutics and enlists all their major and minor projects
- The report assesses Cancer Cachexia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cancer Cachexia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Eli Lilly and Company
  • Helsinn Healthcare S.A.
  • Incyte Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cancer Cachexia Overview

Therapeutics Development

Pipeline Products for Cancer Cachexia - Overview

Pipeline Products for Cancer Cachexia - Comparative Analysis

Cancer Cachexia - Therapeutics under Development by Companies

Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes

Cancer Cachexia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Cancer Cachexia - Products under Development by Companies

Cancer Cachexia - Products under Investigation by Universities/Institutes

Cancer Cachexia - Companies Involved in Therapeutics Development

Acacia Pharma Limited

Aeterna Zentaris Inc.

Aphios Corporation

Atara Biotherapeutics, Inc.

Eli Lilly and Company

Helsinn Healthcare S.A.

Incyte Corporation

Lakewood-Amedex Inc

Novartis AG

Obexia AG

PsiOxus Therapeutics Limited

RaQualia Pharma Inc.

Viking Therapeutics, Inc.

Cancer Cachexia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(formoterol fumarate + megestrol acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anamorelin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUSRM-057 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

espindolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Foxo1-nRNA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landogrozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBX-1201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Cancer Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer Cachexia - Dormant Projects

Cancer Cachexia - Discontinued Products

Cancer Cachexia - Product Development Milestones

Featured News & Press Releases

Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130

Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference

Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study

Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia

Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102

Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics

Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June

Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia

Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 108List of Tables

Number of Products under Development for Cancer Cachexia, H2 2016

Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2016

Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2016

Cancer Cachexia - Pipeline by Aphios Corporation, H2 2016

Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2016

Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2016

Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2016

Cancer Cachexia - Pipeline by Incyte Corporation, H2 2016

Cancer Cachexia - Pipeline by Lakewood-Amedex Inc, H2 2016

Cancer Cachexia - Pipeline by Novartis AG, H2 2016

Cancer Cachexia - Pipeline by Obexia AG, H2 2016

Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2016

Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2016

Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Cancer Cachexia - Dormant Projects, H2 2016

Cancer Cachexia - Dormant Projects (Contd..1), H2 2016

Cancer Cachexia - Discontinued Products, H2 2016 94List of Figures

Number of Products under Development for Cancer Cachexia, H2 2016

Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Eli Lilly and Company
  • Helsinn Healthcare S.A.
  • Incyte Corporation
  • MORE
According to our recently published report 'Cancer Cachexia – Pipeline Review, H2 2016'; Cancer Cachexia pipeline therapeutics constitutes close to 26 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Cancer Cachexia Cancer Cachexia is a multifactorial syndrome that negatively impacts the functional performance, quality of life and prognosis of cancer patients. It is characterized by loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Symptoms include skeletal muscle wasting, weight loss and loss of appetite. Treatment includes appetite stimulants and change in life style.

The report 'Cancer Cachexia – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 1, 1, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Acacia Pharma Limited
Aeterna Zentaris Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Eli Lilly and Company
Helsinn Healthcare S.A.
Incyte Corporation
Lakewood-Amedex Inc
Novartis AG
Obexia AG
PsiOxus Therapeutics Limited
RaQualia Pharma Inc.
Viking Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll